Pharma Mar, S.A. (PHMMF)
USD 88.18
(-16.49%)
USD 88.18
(-16.49%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.54 Million EUR | -99.25% |
| 2022 | 52.06 Million EUR | -47.76% |
| 2021 | 104.08 Million EUR | -33.44% |
| 2020 | 155.94 Million EUR | 1465.22% |
| 2019 | -11.44 Million EUR | -58.67% |
| 2018 | -9.47 Million EUR | 32.46% |
| 2017 | -12.54 Million EUR | 8.56% |
| 2016 | -12.24 Million EUR | -166.01% |
| 2015 | 17.76 Million EUR | -32.14% |
| 2014 | 26.13 Million EUR | 5.34% |
| 2013 | 24.83 Million EUR | 15.29% |
| 2012 | 21.42 Million EUR | 56.2% |
| 2011 | 30.29 Million EUR | 428.36% |
| 2010 | -4.18 Million EUR | 84.5% |
| 2009 | -15.92 Million EUR | 16.89% |
| 2008 | -36.82 Million EUR | 28.35% |
| 2007 | -40.82 Million EUR | -7.57% |
| 2006 | -42.14 Million EUR | -827.18% |
| 2005 | -33.66 Million EUR | 118.02% |
| 2004 | 293 Thousand EUR | 111.88% |
| 2003 | -22.37 Million EUR | 45.36% |
| 2002 | -40.95 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -3.39 Million EUR | 25.12% |
| 2024 Q3 | 7 Million EUR | 287.55% |
| 2024 Q2 | 825 Thousand EUR | 165.59% |
| 2023 FY | - EUR | -99.25% |
| 2023 Q4 | -3.67 Million EUR | -884.43% |
| 2023 Q3 | 469 Thousand EUR | -91.86% |
| 2023 Q2 | 5.76 Million EUR | 511.72% |
| 2023 Q1 | -1.39 Million EUR | -116.15% |
| 2022 FY | - EUR | -47.76% |
| 2022 Q1 | 23.71 Million EUR | -53.59% |
| 2022 Q2 | 9.07 Million EUR | -61.73% |
| 2022 Q4 | 8.66 Million EUR | -32.66% |
| 2022 Q3 | 12.86 Million EUR | 41.79% |
| 2021 Q3 | 5.93 Million EUR | -78.56% |
| 2021 FY | - EUR | -33.44% |
| 2021 Q1 | 19.26 Million EUR | 49.33% |
| 2021 Q2 | 27.68 Million EUR | 43.67% |
| 2021 Q4 | 51.09 Million EUR | 760.83% |
| 2020 FY | - EUR | 1465.22% |
| 2020 Q1 | 72.08 Million EUR | 3377.09% |
| 2020 Q3 | 24.23 Million EUR | -48.42% |
| 2020 Q4 | 12.9 Million EUR | -46.75% |
| 2020 Q2 | 46.98 Million EUR | -34.81% |
| 2019 Q2 | -3.18 Million EUR | 58.28% |
| 2019 Q4 | 2.07 Million EUR | 176.92% |
| 2019 Q1 | -7.63 Million EUR | 11.92% |
| 2019 Q3 | -2.69 Million EUR | 15.38% |
| 2019 FY | - EUR | -58.67% |
| 2018 Q1 | -888 Thousand EUR | 84.92% |
| 2018 Q4 | -8.66 Million EUR | -63.09% |
| 2018 Q2 | 7.73 Million EUR | 971.28% |
| 2018 Q3 | -5.31 Million EUR | -168.7% |
| 2018 FY | - EUR | 32.46% |
| 2017 Q1 | 199 Thousand EUR | 103.06% |
| 2017 Q4 | -5.88 Million EUR | -35.74% |
| 2017 FY | - EUR | 8.56% |
| 2017 Q3 | -4.33 Million EUR | -565.18% |
| 2017 Q2 | -652 Thousand EUR | -427.64% |
| 2016 Q4 | -6.5 Million EUR | -5189.43% |
| 2016 FY | - EUR | -166.01% |
| 2016 Q2 | -1.68 Million EUR | 57.25% |
| 2016 Q3 | -123 Thousand EUR | 92.68% |
| 2016 Q1 | -3.93 Million EUR | -430.14% |
| 2015 Q1 | 9.48 Million EUR | 1832.59% |
| 2015 FY | - EUR | -32.14% |
| 2015 Q4 | 1.19 Million EUR | -83.26% |
| 2015 Q3 | 7.11 Million EUR | 711500.0% |
| 2015 Q2 | -1000.00 EUR | -100.01% |
| 2014 Q4 | 491 Thousand EUR | -86.22% |
| 2014 FY | - EUR | 5.34% |
| 2014 Q3 | 3.56 Million EUR | 28.54% |
| 2014 Q2 | 2.77 Million EUR | -85.65% |
| 2014 Q1 | 19.31 Million EUR | 769.86% |
| 2013 Q3 | 2.2 Million EUR | 4.01% |
| 2013 Q4 | 2.22 Million EUR | 0.68% |
| 2013 FY | - EUR | 15.29% |
| 2013 Q1 | 18.2 Million EUR | 7037.65% |
| 2013 Q2 | 2.12 Million EUR | -88.35% |
| 2012 Q3 | -1.03 Million EUR | -105.31% |
| 2012 FY | - EUR | 56.2% |
| 2012 Q1 | -3.4 Million EUR | -115.4% |
| 2012 Q2 | 19.42 Million EUR | 670.94% |
| 2012 Q4 | 255 Thousand EUR | 124.73% |
| 2011 Q1 | -2.27 Million EUR | 66.94% |
| 2011 Q4 | 22.09 Million EUR | 1065.73% |
| 2011 FY | - EUR | 428.36% |
| 2011 Q3 | -2.28 Million EUR | -244.35% |
| 2011 Q2 | 1.58 Million EUR | 169.67% |
| 2010 Q1 | 239 Thousand EUR | 101.16% |
| 2010 Q2 | 1.97 Million EUR | 727.62% |
| 2010 FY | - EUR | 84.5% |
| 2010 Q3 | 479 Thousand EUR | -75.78% |
| 2010 Q4 | -6.88 Million EUR | -1536.53% |
| 2009 Q3 | -2.25 Million EUR | 27.69% |
| 2009 Q1 | -1 Million EUR | 91.11% |
| 2009 Q2 | -3.11 Million EUR | -210.37% |
| 2009 FY | - EUR | 16.89% |
| 2009 Q4 | -20.57 Million EUR | -813.86% |
| 2008 Q4 | -11.27 Million EUR | 10.02% |
| 2008 Q3 | -12.53 Million EUR | -3259.52% |
| 2008 Q2 | -373 Thousand EUR | 96.29% |
| 2008 Q1 | -10.04 Million EUR | 0.0% |
| 2008 FY | - EUR | 28.35% |
| 2007 FY | - EUR | -7.57% |
| 2006 FY | - EUR | -827.18% |
| 2005 FY | - EUR | 118.02% |
| 2004 FY | - EUR | 111.88% |
| 2003 FY | - EUR | 45.36% |
| 2002 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bioxytran, Inc. | -3.82 Million USD | 219.079% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 106.404% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 2002.153% |
| SQZ Biotechnologies Company | -64.14 Million USD | 107.092% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 272.021% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 126.189% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 95.163% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 396.149% |
| Marizyme, Inc. | -34.28 Million USD | 113.27% |
| Genus plc | 73.7 Million USD | 93.828% |
| Pharming Group N.V. | 9.87 Million USD | 53.944% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 405.833% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 228.249% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 151.858% |
| ContraFect Corporation | -64.99 Million USD | 106.999% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 424.509% |
| IMV Inc. | -35.52 Million USD | 112.806% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 295.755% |
| ONE Bio Corp. | 13.61 Million USD | 66.584% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 109.432% |
| Mesoblast Limited | -62.38 Million USD | 107.291% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 978.107% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | -27.352% |
| Genscript Biotech Corporation | -248.71 Million USD | 101.829% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 819.316% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 299.125% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 176.726% |
| Biomind Labs Inc. | -1.03 Million USD | 539.709% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 257.278% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 163.522% |
| Skye Bioscience, Inc. | -13.54 Million USD | 133.578% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -67553.183% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 168.804% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 18296.0% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 200.504% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 217.112% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 128.665% |
| Accustem Sciences Inc. | -3.74 Million USD | 221.423% |
| EV Biologics, Inc. | -1.26 Million USD | 459.0% |
| Q BioMed Inc. | -617.62 Thousand USD | 836.527% |
| GB Sciences, Inc. | -1.41 Million USD | 420.378% |
| Alpha Cognition Inc. | -9.7 Million USD | 146.87% |
| CSL Limited | 4.78 Billion USD | 99.905% |
| Agentix Corp. | -1.37 Million USD | 431.619% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 111.477% |
| Enzolytics Inc. | -2.12 Million USD | 314.37% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | -11.74 Million USD | 138.741% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 248.514% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 281.817% |
| argenx SE | -216.02 Million USD | 102.106% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 108.22% |
| HST Global, Inc. | -5303.00 USD | 85881.633% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -273.788% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 321.147% |
| Halberd Corporation | -74.27 Thousand USD | 6224.207% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 48.621% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -1100.758% |
| Zenith Capital Corp. | -8.6 Million USD | 152.858% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 403.488% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 285.942% |
| AVAX Technologies, Inc. | -6.11 Million USD | 174.42% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 2684.301% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 336.815% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 26212.163% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | 539.603% |
| Helix BioMedix, Inc. | -1.04 Million USD | 534.765% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 359.943% |
| Kadimastem Ltd | -2.62 Million USD | 273.336% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | 160.223% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 2612.038% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | 412.28 Thousand USD | -1003.368% |
| Cell Source, Inc. | -4.27 Million USD | 206.471% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 1338.764% |
| Regen BioPharma, Inc. | 1.46 Million USD | -210.309% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 585.512% |
| Affymax, Inc. | -14.29 Million USD | 131.822% |
| Mobile Lads Corp. | -2.24 Million USD | 302.975% |
| Itoco Inc. | -1.86 Million USD | 343.393% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 1298.304% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 507.616% |
| International Stem Cell Corporation | 202 Thousand USD | -2151.98% |
| CytoDyn Inc. | -18.02 Million USD | 125.232% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 5856.115% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 37298.463% |
| Qrons Inc. | -40.08 Thousand USD | 11449.517% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 1036.629% |
| SYBLEU INC | -141.57 Thousand USD | 3313.229% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -762.479% |
| Rebus Holdings, Inc. | -951 Thousand USD | 578.339% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 528.339% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 8741.717% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 284.774% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 112.682% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 10208.889% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 266.143% |
| Neutra Corp. | -181.24 Thousand USD | 2609.835% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 122.566% |
| PureTech Health plc | -11.62 Million USD | 139.124% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 122.567% |
| IXICO plc | -707 Thousand USD | 743.423% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 159.193% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 109.409% |
| CSL Limited | 4.73 Billion USD | 99.904% |
| Cellectis S.A. | -92.63 Million USD | 104.911% |